N

Neurimmune AG

65 employees

Neurimmune develops innovative immunotherapeutics for human diseases.

Investor insights

Sectors invested in

Ophthalmology1
Therapeutics1
Diabetic Retinopathy1
Regenerative Therapy1
Biotechnology1

Funding rounds participated in

$10M sweet spot round size

Most of their 2 investments are in rounds between $10M and $10M

Basic info

Industry

pharmaceutical manufacturing

Sectors

type 2 diabetes
Biotechnology
Pharmaceutical
drug development
ALS
Biotech
therapeutics
Information Technology
drug discovery
neuroscience
Parkinsons's disease
human antibodies
Alzheimer's disease
cardiomyopathy

Date founded

2006

Investments made

N

NovaGo Therapeutics raised $10M on March 4, 2019

Investors: Pureos Bioventures, Kinled Holding Ltd and Neurimmune AG

U

Undisclosed raised undisclosed on December 8, 2016

Investors: TVM Capital and Neurimmune AG

Funding rounds raised

Total raised

$150M

from 1 investors over 1 rounds

N

Neurimmune AG raised $150M on October 25, 2017

Investors: Biogen Idec

FAQ